Welcome to our dedicated page for Evolent Health news (Ticker: EVH), a resource for investors and traders seeking the latest updates and insights on Evolent Health stock.
Evolent Health, Inc. (NYSE: EVH) regularly issues news and updates that reflect its focus on better health outcomes for people with complex conditions and on specialty care solutions for payers and providers. Company news often highlights developments in oncology and other complex specialties, financial performance, strategic transactions and leadership changes.
Investors and industry observers following EVH news can expect recurring coverage of quarterly and annual financial results, including revenue and adjusted EBITDA metrics and management commentary on demand for complex specialty care solutions. Evolent frequently reaffirms or updates its financial guidance through press releases and related 8-K filings, and schedules conference calls and webcasts to discuss these results.
Evolent’s news flow also features clinical and partnership initiatives. For example, the company has announced a national partnership with American Oncology Network to introduce a model for cancer care that seeks to improve quality and affordability while reducing reliance on prior authorization. This model incorporates quality initiatives, AI-driven clinical insights through the MiBA analytics platform, payment innovation, and care navigation programs that use a cancer care management platform to support patients.
Corporate and capital markets announcements form another key part of EVH news. Recent items include the pricing and issuance of 4.50% convertible senior notes due 2031, repurchases of existing convertible notes and Class A common stock, and amendments to credit agreements and commitment letters for incremental financing facilities. Evolent also publishes updates on strategic portfolio actions, such as the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group, Inc.
Governance and leadership updates appear in the news as well, including appointments to executive roles, changes in the Chief Financial Officer position, and board retirements and appointments. For readers tracking EVH, this news page offers an ongoing view into how the company communicates its financial performance, specialty care initiatives, capital structure decisions and organizational evolution.
Evolent Health (NYSE: EVH) will announce its Q2 2024 financial results on August 8, 2024, post-market close, followed by a conference call at 5 p.m. ET. Interested participants can access the live broadcast via Evolent's investor relations website or join the call by dialing 855.940.9467 (domestic) or 412.317.6034 (international), referencing the 'Evolent call'. An audio playback will be available on the website for 90 days post-call.
Evolent's executive team will also participate in investor conferences, including the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2024, and the 2024 Bernstein Disruptor Conference in New York on September 24, 2024. Webcasts for these events, if available, will be accessible through their investor relations site.
Evolent Health (EVH) has announced an agreement to acquire certain assets and an exclusive license for Machinify Auth, a proven AI software platform.
This acquisition aims to enhance Evolent's specialty condition management platform through AI-enabled clinical workflow automation.
Machinify's technology uses machine learning, large language models, and data analytics to improve clinical quality, speed, and consistency.
Expected benefits include increased first-pass approvals, streamlined data collection, and reduced clinician workforce time by 55%.
The acquisition, deemed neutral to Adjusted EBITDA in the first year, is expected to close in Q3 2024.
Evolent Health, Inc. (NYSE: EVH) has announced a strategic partnership with digital cancer care platform Careology to enhance cancer care in the U.S. This collaboration aims to provide more coordinated, connected, and empowered journeys for individuals living with cancer. By integrating Careology's digital cancer care technology into Evolent's comprehensive care navigation services, the joint platform will offer personalized information, tools, and support to help patients manage their diagnoses and treatment regimens more effectively. The partnership comes at a important time as global cancer rates are expected to increase significantly, and the U.S. faces challenges such as rising costs and drug shortages in cancer care.
Evolent Health, Inc. announced strong first quarter results, with a revenue increase of 49.6% to $639.7 million and an Adjusted EBITDA of $54.1 million. The company raised its revenue outlook for full year 2024 and reiterated its Adjusted EBITDA guidance. Evolent also highlighted new revenue agreements and an exclusive partnership with Careology. Despite a net loss of $(25.2) million, the CEO remains optimistic about the company's growth potential.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.